Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496046 | 0.93 | LPAR3 (0.44) | LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL6493288 | 0.89 | POLB (0.39) | CYP3A4POLBGAACA12CA1 | |
| SCHEMBL7110468 | 0.85 | ALDH1A1 (0.41) | CYP3A4LPAR3LPAR1CA12CA1 | |
| SCHEMBL2637224 | 0.83 | POLB (0.42) | CYP3A4POLBGAATSHRALDH1A1 | |
| SCHEMBL6492056 | 0.79 | POLB (0.46) | POLBGAATSHR | |
| SCHEMBL7103296 | 0.79 | LPAR3 (0.43) | LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL6483396 | 0.78 | POLB (0.44) | POLBGAATSHR | |
| SCHEMBL3633847 | 0.76 | POLB (0.42) | CYP3A4POLBGAATSHRCYP2C9 | |
| SCHEMBL7644205 | 0.74 | CYP3A4 (0.35) | CYP3A4POLBGAACA12CA1 | |
| SCHEMBL2976621 | 0.73 | POLB (0.40) | CYP3A4POLBGAATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867218-B2 | Compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2005-03-15 | — | — | US | disclosed |
| US-20030195200-A1 | Compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-10-16 | — | — | US | disclosed |
| US-6555577-B1 | For treatment and/or prevention of conditions mediated by the Peroxisome Proliferator-Activated Receptors (PPAR), such as diabetes and/or obesity; 3-(4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl)-2-butoxy-propionic acid for example | NOVO NORDISK A/S (DE) | 2003-04-29 | — | — | US | disclosed |
| EP-1254101-A1 | PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | Novo Nordisk A/S (DK) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055085-A1 | PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | NOVO NORDISK A/S (DK) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195200-A1 | Compounds, their preparation and use | PPARG, PPARA, PPARD | CYP3A4 540/4885POLB 886/4885LPAR3 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.